Nanobiotix S.A. announced it has appointed Edwina Baskin-Bey, M.D. as its new CMO. Dr. Baskin-Bey succeeds Elsa Borghi, M.D., who will remain focused on the early development of innovative products at Nanobiotix. Dr. Baskin-Bey brings over 18 years of oncology clinical development and basic science experience in academia and industry, most recently serving as CMO of North Carolina-based oncology start-up, Innocrin Pharmaceuticals. As a member of the Executive Team at Innocrin, Dr. Baskin-Bey led development and implementation of the overall clinical and corporate strategy from phase I to phase III. She was responsible for the Medical, Regulatory, Pharmacovigilance, Clinical Operations, Biostatistics, and Data Management functions.